Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
Phase 2
Not yet recruiting
- Conditions
- RECTAL NEOPLASMSRectal Cancer
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT06390982
clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
Recruiting
- Conditions
- Breast CancerBone Metastases
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 500
- Registration Number
- NCT06392217
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- TNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 74
- Registration Number
- NCT06387628
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Phase 1
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 117
- Registration Number
- NCT06370754
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Transcriptomic Analysis of Incisional Hernia Based on High-throughput Sequencing Technology
Completed
- Conditions
- Incisional HerniaExtracellular Matrix Alteration
- Interventions
- Diagnostic Test: Transcriptomic analysis
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06366581
- Locations
- 🇨🇳
Hua Dong Hospital Affiliated to Fu Dan University, Shanghai, China
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Recruiting
- Conditions
- Non-small Cell Lung CancerHistology TransformationNeuroendocrine Carcinoma
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06369181
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Phase 2
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 81
- Registration Number
- NCT06359275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanhai, China
Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 150
- Registration Number
- NCT06356519
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06355024
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06355037
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath